Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
Assembly Biosciences, Inc. (ASMB)
Last assembly biosciences, inc. earnings: 3/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.assemblybio.com/investor-relations
Company Research
Source: GlobeNewswire
– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation – – Phase 1b data from ABI-1179 accepted for late-breaker poster presentation – SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced Phase 1b clinical data for ABI-5366 and ABI-1179, herpes simplex virus (HSV) helicase-primase inhibitor candidates, will be featured in multiple presentations, including one late-breaker, at the 2026 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) taking place April 17-21, 2026, in Munich, Germany. “The selection of ABI-5366 for oral presentation at ESCMID underscores the strength and clinical relevance of the data generated to date, including additional results from the monthly dosing cohort,” said Anuj Gaggar, MD, PhD, chief medi
Show less
Read more
Impact Snapshot
Event Time:
ASMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASMB alerts
High impacting Assembly Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ASMB
News
- Assembly Biosciences (ASMB) had its price target raised by Guggenheim from $39.00 to $43.00. They now have a "buy" rating on the stock.MarketBeat
- Assembly Biosciences (ASMB) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ASMB&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "buyMarketBeat
- Assembly Biosciences (ASMB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.MarketBeat
- Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights [Yahoo! Finance]Yahoo! Finance
- Assembly Biosciences: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
ASMB
Sec Filings
- 3/31/26 - Form 4
- 3/31/26 - Form 4
- 3/31/26 - Form 4
- ASMB's page on the SEC website